Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi‐Organ Failure

• मुख्य लेखकों: Fatih M. Uckun (लेखक), James Carlson (लेखक), Cemal Orhan (लेखक), Joy Powell (लेखक), Natalie M. Pizzimenti (लेखक), Hendrik van Wyk (लेखक), Ibrahim H. Ozercan (लेखक), Michael Volk (लेखक), Kazim Sahin (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2020-11-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Background: New treatment platforms that can prevent acute respiratory distress syndrome (ARDS) or reduce its mortality rate in high-risk coronavirus disease 2019 (COVID-19) patients, such as those with an underlying cancer, are urgently needed. Rejuveinix (RJX) is an intravenous formulation of anti...